Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.

Journal of cellular and molecular medicine - 1 Sept 2025

Qi Wenxin, Zhang Yuqi, Hao Xiaoyu, Yang Ping, Wang Jing, Wu Chaoling, Zhang Weilong, Jing Hongmei

Abstract excerpt

P53 mutation (TP53m) is a common intrinsic factor involved in relapsed or refractory (R/R) B cell malignancies that associates with treatment resistance. As a novel immunotherapy, CAR-T has been increasingly applied in TP53m B cell malignancies, yet whether it can overcome the poor outcome of the TP53m population is controversial. We searched MEDLINE and EMBASE to identify population-based cohort studies that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to TP53 gene
Share to Immunotherapy, Adoptive

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, B-Cell

Share to Lymphoma, B-Cell

Share to Mutation

Share to Receptors, Chimeric Antigen

Share to Treatment Outcome

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 40984040
DOI: 10.1111/jcmm.70818
PMCID: PMC12454170

Genes

CD19
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes of Wild Type and TP53-Mutated B Cell Malignancy Patients Receiving CAR-T Cell Therapy: A Systematic Review and Meta-Analysis.PMID 40984040Read ↗

Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.Semantic proximity Read ↗

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.Semantic proximity Read ↗

TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis.Semantic proximity Read ↗

TP53 mutation and survival in aggressive B cell lymphoma.Semantic proximity Read ↗

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.Semantic proximity Read ↗

Cancer type-dependent correlations between TP53 mutations and antitumor immunity.Semantic proximity Read ↗

Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL.Semantic proximity Read ↗

Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.Semantic proximity Read ↗

A CAR-T response prediction model for r/r B-NHL patients based on a T-cell subset nomogramSemantic proximity Read ↗

TP53 mutations and rituximab-CHOP.Semantic proximity Read ↗

Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.Semantic proximity Read ↗

MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.